Cabot (NYSE:CBT – Get Free Report) updated its FY25 earnings guidance on Monday. The company provided earnings per share guidance of $7.40-7.80 for the period, compared to the consensus earnings per share estimate of $7.85. Cabot also updated its FY 2025 guidance to 7.400-7.800 EPS.
Cabot Stock Up 1.0 %
Shares of CBT stock traded up $1.07 during mid-day trading on Monday, reaching $110.09. 709,694 shares of the company’s stock traded hands, compared to its average volume of 336,001. The company has a market cap of $6.04 billion, a P/E ratio of 13.15, a P/E/G ratio of 0.90 and a beta of 1.20. The company has a quick ratio of 1.45, a current ratio of 2.22 and a debt-to-equity ratio of 0.72. Cabot has a 12 month low of $66.02 and a 12 month high of $117.14. The company’s 50-day moving average price is $108.20 and its 200-day moving average price is $100.87.
Cabot (NYSE:CBT – Get Free Report) last released its earnings results on Monday, August 5th. The specialty chemicals company reported $1.92 EPS for the quarter, topping the consensus estimate of $1.72 by $0.20. Cabot had a return on equity of 26.99% and a net margin of 12.05%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1 billion. During the same period in the previous year, the company posted $1.42 earnings per share. The company’s revenue for the quarter was up 5.0% compared to the same quarter last year. On average, equities analysts expect that Cabot will post 7.07 earnings per share for the current fiscal year.
Analysts Set New Price Targets
View Our Latest Report on Cabot
Insider Buying and Selling at Cabot
In other news, CFO Erica Mclaughlin sold 23,274 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $99.79, for a total value of $2,322,512.46. Following the completion of the sale, the chief financial officer now directly owns 59,814 shares of the company’s stock, valued at $5,968,839.06. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Cabot news, CEO Sean D. Keohane sold 25,617 shares of the stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $101.55, for a total value of $2,601,406.35. Following the sale, the chief executive officer now owns 331,174 shares in the company, valued at $33,630,719.70. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Erica Mclaughlin sold 23,274 shares of Cabot stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $99.79, for a total transaction of $2,322,512.46. Following the transaction, the chief financial officer now directly owns 59,814 shares in the company, valued at approximately $5,968,839.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 71,939 shares of company stock valued at $7,308,812 over the last 90 days. 3.07% of the stock is currently owned by corporate insiders.
Cabot Company Profile
Cabot Corporation operates as a specialty chemicals and performance materials company. The company operates through two segments, Reinforcement Materials and Performance Chemicals. It offers reinforcing carbons that are used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and engineered elastomer composites solutions.
Further Reading
- Five stocks we like better than Cabot
- Overbought Stocks Explained: Should You Trade Them?
- Intel: Is Now the Time to Be Brave?Â
- The How And Why of Investing in Oil Stocks
- Carnival or Royal Caribbean—Which Cruise Stock Has More Upside?
- Election Stocks: How Elections Affect the Stock Market
- Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.